Placebo to Etanercept

DRUG2 trials

Sponsors

Sun Pharmaceutical Industries Limited, Amgen

Conditions

Plaque-type PsoriasisPsoriatic Arthritis

Phase 3

A Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous MK-3222 in Participants With Moderate-to-Severe Chronic Plaque Psoriasis (MK-3222-012)

WithdrawnNCT01936688

Sun Pharmaceutical Industries LimitedPlaque-type Psoriasis

Start: 2013-09-30End: 2018-08-31Updated: 2022-02-24

Etanercept and Methotrexate in Combination or as Monotherapy in Psoriatic Arthritis

CompletedNCT02376790

AmgenPsoriatic Arthritis

Start: 2015-03-03End: 2018-07-06Updated: 2022-09-21

Related Papers

Potential Impact of Sex and BMI on Response to Therapy in Psoriatic Arthritis: Post Hoc Analysis of Results From the SEAM-PsA Trial

The Journal of Rheumatology2022-04-1517 citations

Performance of composite measures used in a trial of etanercept and methotrexate as monotherapy or in combination in psoriatic arthritis

Lara D. Veeken2020-04-2814 citations